Disclosures for "Prevalence of Pathogenic CSF1R Variants in a Large Genomic Cohort: Insights from the Mayo Tapestry Study "
-
Dr. Milanowski has nothing to disclose.
-
Dr. Chmiela has nothing to disclose.
-
The institution of Dr. Tacik has received research support from Merz Therapeutics, Ipsen Pharma, Anavex Life Sciences Corp. The institution of Dr. Tacik has received research support from Merz Therapeutics, Ipsen Pharma, AbbVie Germany, Boston Scientific Medical Technology, Medtronic. Dr. Tacik has received personal compensation in the range of $5,000-$9,999 for serving as a speaker with Merz Therapeutics, Ipsen Pharma.
-
Dr. Olson has nothing to disclose.
-
Dr. Ross has nothing to disclose.
-
Dr. Wszolek has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Polish Neurological Society/Via Medica. Dr. Wszolek has received intellectual property interests from a discovery or technology relating to health care.